EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapies
Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes.
Read original article on The Medical News →Related news
-
Virtual reality and classical music help to reduce blood pressure in patients in emergency department
United Kingdom
-
Drones could speed up delivery of automated external defibrillators to patients suffering cardiac arrest
United Kingdom
-
Steatotic liver disease risk scores compared for predicting cirrhosis
United Kingdom
-
Tapping the power of cryo-ET to visualize how molecular machines interact inside cells
United Kingdom
-
UC researcher receives funding to study bone complications in people with sickle cell disease
United Kingdom
-
Aga's restaurant in Houston is number one in the world for Uber Eats deliveries
United States
-
UM birding program can help stroke survivors with aphasia
United Kingdom
-
Existing drug helps bladder cells destroy hidden urinary tract infections
United Kingdom